NASDAQ · COEP
Coeptis Therapeutics Holdings, Inc.
$10.99-$1.03 (-8.57%)
Coeptis Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.67% below the high.
Loading market information…
OTC · SYRS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Syros Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Syros Pharmaceuticals, Inc.’s next earnings report is currently expected on Oct 30, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Syros Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily focused on discovering and developing novel therapeutic solutions for various cancers and monogenic (single-gene) diseases. A key strategic aim for the company involves cultivating a robust pipeline of medicines that modulate gene expression. Its leading investigational drug candidates include: Tamibarotene: A selective retinoic acid receptor alpha agonist, currently undergoing Phase III clinical trials for a genetically defined subset of patients with myelodysplastic syndrome, and in Phase II trials for individuals suffering from acute myeloid leukemia. SY-2101: An innovative oral formulation of arsenic trioxide, intended for the treatment of acute promyelocytic leukemia. SY-5609: A cyclin-dependent kinase 7 inhibitor, which is being assessed in a Phase I clinical study involving patients with specific advanced solid tumors. Syros maintains several strategic alliances, notably a research collaboration and option agreement with Incyte Corporation centered on identifying therapeutic targets for myeloproliferative neoplasms. Furthermore, the company has a licensing arrangement with TMRC Co. Ltd. pertaining to the development and commercialization of tamibarotene. Initially incorporated in 2011 as LS22, Inc., the company officially adopted the name Syros Pharmaceuticals, Inc. in August 2012. Its corporate headquarters are located in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Nov 14, 2023 |
| -$1.35-20.54% vs estimate |
| $3.76M+88.1% vs estimate |
| Q2 2023 | Aug 8, 2023 | -$1.30-17.12% vs estimate | $2.83M-19.06% vs estimate |
|---|
| Q1 2023 | May 10, 2023 | -$0.85+24.11% vs estimate | $2.95M-9.39% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.99-$1.03 (-8.57%)
Coeptis Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.67% below the high.
$0.38+$0.01 (+2.81%)
Pasithea Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 81.55% below the high.
₪0.01₪0.00 (0.0%)
Purple Biotech Ltd.’s quoted price sits in the upper half of its reported 52-week range, 37.5% below the high.
$0.17+$0.17 (+100.0%)
Holdco Nuvo Group D.G Ltd. Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 22.73% below the high.
$0.80-$0.04 (-4.89%)
Dermata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.83% below the high.
$3.72-$0.03 (-0.79%)
Revelation Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.84% below the high.
$0.01$0.00 (0.0%)
NKGen Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.56% below the high.
$0.02$0.00 (0.0%)
Vincerx Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.95% below the high.
